Oligomerization of G-Protein- Coupled Transmitter Receptors
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Hecate-Cgb Conjugate and Gonadotropin Suppression Shows Two Distinct Mechanisms of Action in the Treatment of Adrenocortical
Endocrine-Related Cancer (2009) 16 549–564 Hecate-CGb conjugate and gonadotropin suppression shows two distinct mechanisms of action in the treatment of adrenocortical tumors in transgenic mice expressing Simian Virus 40 T antigen under inhibin-a promoter Susanna Vuorenoja1,2, Bidut Prava Mohanty1, Johanna Arola3, Ilpo Huhtaniemi1,4, Jorma Toppari1,2 and Nafis A Rahman1 Departments of 1Physiology and 2Pediatrics, University of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland 3Department of Pathology, University of Helsinki and HUSLAB, Helsinki, Finland 4Institute of Reproductive and Developmental Biology, Imperial College, London, UK (Correspondence should be addressed to N A Rahman; Email: nafis.rahman@utu.fi) Abstract Lytic peptide Hecate (23-amino acid (AA)) fused with a 15-AA fragment of human chorionic gonadotropin-b (CG-b), Hecate-CGb conjugate (H-CGb-c) selectively binds to and destroys tumor cells expressing LH/chorionic gonadotropin receptor (Lhcgr). Transgenic mice (6.5 month old) expressing SV40 T-antigen under the inhibin-a promoter (inha/Tag) presenting with Lhcgr expressing adrenal tumors were treated either with H-CGb-c, GnRH antagonist (GnRH-a), estradiol (E2; only females) or their combinations for 1 month. We expected that GnRH-a or E2 in combination with H-CGb-c could improve the treatment efficacy especially in females by decreasing circulating LH and eliminating the potential competition of serum LH with the H-CGb-c. GnRH-a and H-CGb-c treatments were successful in males (adrenal weights 14G2.8 mg and 60G26 vs 237G59 mg in controls; P!0.05). Histopathologically, GnRH-a apparently destroyed the adrenal parenchyma leaving only the fibrotic capsule with few necrotic foci. -
Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder. -
The Roles Played by Highly Truncated Splice Variants of G Protein-Coupled Receptors Helen Wise
Wise Journal of Molecular Signaling 2012, 7:13 http://www.jmolecularsignaling.com/content/7/1/13 REVIEW Open Access The roles played by highly truncated splice variants of G protein-coupled receptors Helen Wise Abstract Alternative splicing of G protein-coupled receptor (GPCR) genes greatly increases the total number of receptor isoforms which may be expressed in a cell-dependent and time-dependent manner. This increased diversity of cell signaling options caused by the generation of splice variants is further enhanced by receptor dimerization. When alternative splicing generates highly truncated GPCRs with less than seven transmembrane (TM) domains, the predominant effect in vitro is that of a dominant-negative mutation associated with the retention of the wild-type receptor in the endoplasmic reticulum (ER). For constitutively active (agonist-independent) GPCRs, their attenuated expression on the cell surface, and consequent decreased basal activity due to the dominant-negative effect of truncated splice variants, has pathological consequences. Truncated splice variants may conversely offer protection from disease when expression of co-receptors for binding of infectious agents to cells is attenuated due to ER retention of the wild-type co-receptor. In this review, we will see that GPCRs retained in the ER can still be functionally active but also that highly truncated GPCRs may also be functionally active. Although rare, some truncated splice variants still bind ligand and activate cell signaling responses. More importantly, by forming heterodimers with full-length GPCRs, some truncated splice variants also provide opportunities to generate receptor complexes with unique pharmacological properties. So, instead of assuming that highly truncated GPCRs are associated with faulty transcription processes, it is time to reassess their potential benefit to the host organism. -
Accelerated Resensitization of the D 1 Dopamine Receptor-Mediated
The Journal of Neuroscience, October 1994, 74(10): 6260-6266 Accelerated Resensitization of the D 1 Dopamine Receptor-mediated Response in Cultured Cortical and Striatal Neurons from the Rat: Respective Role of CY1 -Adrenergic and /U-methybaspartate Receptors Fabrice Trovero, Philippe Marin, Jean-PO1 Tassin, JoQl Premont, and Jacques Glowinski INSERM U 114, Chaire de Neuropharmacologie, College de France, 75231 Paris Cedex, France As previously shown in vivo, noradrenergic and glutama- cortex. In the rat, bilateral electrolytic lesions of the mesence- tergic neurons can regulate the denervation supersensitivity phalic ventral tegmental area induce a complex and permanent of Dl dopaminergic (DA) receptors in the rat prefrontal cor- behavioral syndrome characterized by a locomotor hyperactiv- tex and striatum respectively. Therefore, the effects of meth- ity and the incapacity of the animal to focalize its attention (Le oxamine (an al-adrenergic agonist) and glutamate on the Moal et al., 1969). Some of the behavioral deficits observed in resensitization of Dl DA receptors were investigated in cul- the lesioned animals, particularly the locomotor hyperactivity, tured cortical and striatal neurons from the embryonic rat. have been attributed for a large part to the selective destruction In the presence of sulpiride and propranolol, DA stimulated of the cortical dopaminergic (DA) innervation (Tassin et al., the Dl DA receptor-mediated conversion of 3H-adenine into 1978). This locomotor hyperactivity was markedly reduced in 3H-cAMP in both intact cortical and striatal cells and these rats with 6-hydroxydopamine (6-OHDA) lesions,which destroy responses were markedly desensitized in cells preexposed not only the ascendingDA neurons but also the ascendingnor- for 15 min to DA (50 AM). -
GABAB Receptors and Pain
King’s Research Portal DOI: 10.1016/j.neuropharm.2017.05.012 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Malcangio, M. (2017). GABAB receptors and pain. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.05.012 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. -
Determination of Biological Activity of Gonadotropins Hcg and FSH By
www.nature.com/scientificreports OPEN Determination of biological activity of gonadotropins hCG and FSH by Förster resonance energy transfer Received: 14 October 2016 Accepted: 06 January 2017 based biosensors Published: 09 February 2017 Olga Mazina1,2, Anni Allikalt1, Juha S. Tapanainen3, Andres Salumets2,3,4,5 & Ago Rinken1 Determination of biological activity of gonadotropin hormones is essential in reproductive medicine and pharmaceutical manufacturing of the hormonal preparations. The aim of the study was to adopt a G-protein coupled receptor (GPCR)-mediated signal transduction pathway based assay for quantification of biological activity of gonadotropins. We focussed on studying human chorionic gonadotropin (hCG) and follicle-stimulating hormone (FSH), as these hormones are widely used in clinical practice. Receptor-specific changes in cellular cyclic adenosine monophosphate (cAMP, second messenger in GPCR signalling) were monitored by a Förster resonance energy transfer (FRET) biosensor protein TEpacVV in living cells upon activation of the relevant gonadotropin receptor. The BacMam gene delivery system was used for biosensor protein expression in target cells. In the developed assay only biologically active hormones initiated GPCR-mediated cellular signalling. High assay sensitivities were achieved for detection of hCG (limit of detection, LOD: 5 pM) and FSH (LOD: 100 pM). Even the small- scale conformational changes caused by thermal inactivation and reducing the biological activity of the hormones were registered. In conclusion, the proposed assay is suitable for quantification of biological activity of gonadotropins and is a good alternative to antibody- and animal-testing-based assays used in pharmaceutical industry and clinical research. Gonadotropin medications are widely used in controlled ovarian stimulation and induction of ovulation as key components of infertility treatment. -
Β2‑Adrenergic Receptor Functionality and Genotype in Two Different Models of Chronic Inflammatory Disease: Liver Cirrhosis and Osteoarthritis
MOLECULAR MEDICINE REPORTS 17: 7987-7995, 2018 β2‑adrenergic receptor functionality and genotype in two different models of chronic inflammatory disease: Liver cirrhosis and osteoarthritis REYES ROCA1, PABLO ESTEBAN1, PEDRO ZAPATER2,3, MARÍA-DEL-MAR INDA4, ANNA LUCIA CONTE1, LAURA GÓMEZ-ESCOLAR5, HELENA MARTÍNEZ6, JOSÉ F. HORGA3, JOSÉ M. PALAZON5 and ANA M. PEIRÓ3,4 1Occupational Observatory, Miguel Hernández University (UMH) of Elche, 03202 Elche; 2CIBERehd, Carlos III Health Institute, 28029 Madrid; 3Clinical Pharmacology, General Hospital of Alicante; 4Neuropharmacology on Pain (NED) Research Group, ISABIAL-FISABIO, General Hospital of Alicante; 5Liver Unit, General Hospital of Alicante, 03010 Alicante; 6Clinical R&D Area, Bioiberica S.A., 08029 Barcelona, Spain Received June 12, 2017; Accepted September 28, 2017 DOI: 10.3892/mmr.2018.8820 Abstract. The present study was designed to investigate the Introduction functional status of β2 adrenoceptors (β2AR) in two models of chronic inflammatory disease: Liver cirrhosis (LC) and The role of the sympathetic nervous system (SNS) in inflam- osteoarthritis (OA). The β2AR gene contains three single mation is still not completely understood, although it is well nucleotide polymorphisms at amino acid positions 16, 27 and known that disturbed interaction between both contributes to 164. The aim of the present study was to investigate the poten- pathogenic chronic inflammatory diseases (1,2). Evidence for tial influence of lymphocyte β2AR receptor functionality and the possibility of such interaction have been reinforced since genotype in LC and OA patients. Blood samples from cirrhotic the discovery of the expression of beta-2-adrenergic receptor patients (n=52, hepatic venous pressure gradient 13±4 mmHg, (β2AR) on T and B lymphocytes, macrophages, natural killer CHILD 7±2 and MELD 11±4 scores), OA patients (n=30, 84% cells and neutrophils (3-6). -
Discovery of Novel Imidazolines and Imidazoles As Selective TAAR1
Discovery of Novel Imidazolines and Imidazoles as Selective TAAR1 Partial Agonists for the Treatment of Psychiatric Disorders Giuseppe Cecere, pRED, Discovery Chemistry F. Hoffmann-La Roche AG, Basel, Switzerland Biological Rationale Trace amines are known for four decades Trace Amines - phenylethylamine p- tyramine p- octopamine tryptamine (PEA) Biogenic Amines dopamine norepinephrine serotonin ( DA) (NE) (5-HT) • Structurally related to classical biogenic amine neurotransmitters (DA, NE, 5-HT) • Co-localised & released with biogenic amines in same cells and vesicles • Low concentrations in CNS, rapidly catabolized by monoamine oxidase (MAO) • Dysregulation linked to psychiatric disorders such as schizophrenia & 2 depression Trace Amines Metabolism 3 Biological Rationale Trace Amine-Associated Receptors (TAARs) p-Tyramine extracellular TAAR1 Discrete family of GPCR’s Subtypes TAAR1-TAAR9 known intracellular Gs Structural similarity with the rhodopsin and adrenergic receptor superfamily adenylate Activation of the TAAR1 cyclase receptor leads to cAMP elevation of intracellular cAMP levels • First discovered in 2001 (Borowsky & Bunzow); characterised and classified at Roche in 2004 • Trace amines are endogenous ligands of TAAR1 • TAAR1 is expressed throughout the limbic and monoaminergic system in the brain Borowsky, B. et al., PNAS 2001, 98, 8966; Bunzow, J. R. et al., Mol. Pharmacol. 2001, 60, 1181. Lindemann L, Hoener MC, Trends Pharmacol Sci 2005, 26, 274. 4 Biological Rationale Electrical activity of dopaminergic neurons + p-tyramine -
Luteinizing Hormonereleasing Hormone (LHRH) Receptor Agonists Vs Antagonists
Review Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors? Yuri Tolkach, Steven Joniau* and Hendrik Van Poppel* Urology Clinic, Military Medical Academy, Saint-Petersburg, Russia, and *Department of Urology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium Luteinizing hormone-releasing hormone (LHRH) agonists and antagonists are commonly used androgen deprivation therapies prescribed for patients with advanced prostate cancer (PCa). Both types of agent target the receptor for LHRH but differ in their mode of action: agonists, via pituitary LRHR receptors (LHRH-Rs), cause an initial surge in luteinizing hormone (LH), follicle-stimulating hormone (FSH) and, subsequently, testosterone. Continued overstimulation of LHRH-R down-regulates the production of LH and leads to castrate levels of testosterone. LHRH antagonists, however, block LHRH-R signalling causing a rapid and sustained inhibition of testosterone, LH and FSH. The discovery and validation of the presence of functional LHRH-R in the prostate has led to much work investigating the role of LHRH signalling in the normal prostate as well as in the treatment of PCa with LHRH agonists and antagonists. In this review we discuss the expression and function of LHRH-R, as well as LH/human chorionic gonadotropin receptors and FSH receptors and relate this to the differential clinical responses to agonists and antagonists used in the hormonal manipulation of PCa. Keywords androgen deprivation therapy, LHRH agonist, GnRH antagonist, LHRH receptor, prostate cancer Introduction the last 30 years. LHRH agonists, by continually stimulating The most common type of treatment prescribed for the LHRH-R, down-regulate receptor expression in the patients with advanced prostate cancer (PCa) is LHRH pituitary leading to decreased levels of LH, and to a lesser agonists and these are increasingly being used in patients extent, FSH. -
Functioning of the Dimeric GABAB Receptor Extracellular Domain Revealed by Glycan Wedge Scanning
Functioning of the dimeric GABAB receptor extracellular domain revealed by glycan wedge scanning Philippe Rondard1§, Siluo Huang2§, Carine Monnier1, Haijun Tu2, Bertrand Blanchard1, Nadia Oueslati1, Fanny Malhaire1, Ying Li2, Eric Trinquet3, Gilles Labesse4,5, Jean-Philippe Pin1 & Jianfeng Liu2 1 CNRS, UMR 5203, Institut de Génomique Fonctionnelle, Montpellier, France and INSERM, U661, Montpellier, France and Université Montpellier 1,2, Montpellier F-34000, France. 2, Sino-France Laboratory for Drug Screening, Key Laboratory of Molecular Biophysics of Ministry of Education, Huazhong University of Science and Technology, Wuhan, Hubei, China 3 CisBio International, Parc technologique Marcel Boiteux, Bagnols/Cèze cedex F-30204, France 4, Centre de Biochimie Structurale, CNRS UMR5048, Université Montpellier 1, Montpellier F-34060, France 5 INSERM U414, Montpellier, F-34094 France § P.R. and S.H. contributed equally to this work Correspondence should be addressed to J.P.P ([email protected]) and J.L. ([email protected]). Running title : Functional analysis of GABAB receptor VFTs using N-glycans Total character count (including spaces) : 55,058 1 Abstract The G-protein coupled receptor activated by the neurotransmitter GABA is made up of two subunits, GABAB1 and GABAB2. While GABAB1 binds agonists, GABAB2 is required for trafficking GABAB1 to the cell surface, increasing agonist affinity to GABAB1, and activating associated G-proteins. These subunits each comprise two domains, a Venus flytrap (VFT) domain and a heptahelical (7TM) domain. How agonist binding to the GABAB1 VFT leads to GABAB2 7TM activation remains unknown. Here, we used a glycan wedge scanning approach to investigate how the GABAB VFT dimer controls receptor activity. -
Thyrotropin-Luteinizing Hormone/Chorionic Gonadotropin
Proc. Natl. Acad. Sci. USA Vol. 88, pp. 902-905, February 1991 Medical Sciences Thyrotropin-luteinizing hormone/chorionic gonadotropin receptor extracellular domain chimeras as probes for thyrotropin receptor function (hormone binding/signal transduction) Yuji NAGAYAMA, HARRY L. WADSWORTH, GREGORIO D. CHAZENBALK, DIEGO Russo, Pui SETO, AND BASIL RAPOPORT Thyroid Molecular Biology Unit, Veterans Administration Medical Center, San Francisco, CA 94121; and the University of California, San Francisco, CA 94143-0534 Communicated by William J. Rutter, November 2, 1990 ABSTRACT To define the sites in the extracellular domain site(s) involved in ligand binding or the region(s) important in of the human thyrotropin (TSH) receptor that are involved in signal transduction. TSH binding and signal transduction we constructed chimeric Recent studies indicate that ligand- and antibody-binding thyrotropin-luteinizing hormone/chorionic gonadotropin sites in folded globular proteins are conformational and may (TSH-LH/CG) receptors. The extracellular domain of the consist of discontinuous regions of the linear amino acid human TSH receptor was divided into five regions that were sequence (13-17). In studies defining ligand-binding sites in replaced, either singly or in various combinations, with ho- native proteins it is therefore important to conserve the mologous regions of the rat LH/CG receptor. The chimeric three-dimensional structure of the protein. The considerable receptors were stably expressed in Chinese hamster ovary cells. (30-50%) homology in the extracellular domains of the gly- The data obtained suggest that the carboxyl region of the coprotein hormone receptors together with the presence of 10 extracellular domain (amino acid residues 261418) and par- conserved extracellular cysteine residues [some ofwhich are ticularly the middle region (residues 171-260) play a role in thought to form disulfide bonds (12)] suggest a similar three- signal transduction. -
G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes
Int. J. Mol. Sci. 2014, 15, 1112-1142; doi:10.3390/ijms15011112 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes Benoît T. Roux 1 and Graeme S. Cottrell 2,* 1 Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK; E-Mail: [email protected] 2 Reading School of Pharmacy, University of Reading, Reading RG6 6UB, UK * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-118-378-7027; Fax: +44-118-378-4703. Received: 4 December 2013; in revised form: 20 December 2013 / Accepted: 8 January 2014 / Published: 16 January 2014 Abstract: G protein-coupled receptors (GPCRs) are important cell signaling mediators, involved in essential physiological processes. GPCRs respond to a wide variety of ligands from light to large macromolecules, including hormones and small peptides. Unfortunately, mutations and dysregulation of GPCRs that induce a loss of function or alter expression can lead to disorders that are sometimes lethal. Therefore, the expression, trafficking, signaling and desensitization of GPCRs must be tightly regulated by different cellular systems to prevent disease. Although there is substantial knowledge regarding the mechanisms that regulate the desensitization and down-regulation of GPCRs, less is known about the mechanisms that regulate the trafficking and cell-surface expression of newly synthesized GPCRs. More recently, there is accumulating evidence that suggests certain GPCRs are able to interact with specific proteins that can completely change their fate and function. These interactions add on another level of regulation and flexibility between different tissue/cell-types.